March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
A landmark multi-hundred million dollar collaboration between Takeda and BridGene Biosciences redefines biotech funding trends this week, joined …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
Already a subscriber? Log in